NBTX
Nanobiotix S.A. [NBTX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NBTX Stock Summary
Top 10 Correlated Stocks
NBTX
In the News
NBTX Financial details
Company Rating
-
Market Cap
275.43M
Income
-74.13M
Revenue
6.74M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
101
Optionable
No
Shortable
Yes
Earnings
22 Apr 2024
P/E
-4.27
Forward P/E
-
PEG
-0.75
P/S
68.93
P/B
-9
P/C
-
P/FCF
-8.85
Quick Ratio
1.3
Current Ratio
1.38
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.12
EPS next Y
-
EPS next Q
-
EPS this Y
21.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.53%
Revenue last 5Y
110.34%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
6%
SMA50
23.76%
SMA100
300.74%
Inst Own
-
Inst Trans
-
ROA
-95%
ROE
44740%
ROC
-2.14%
Gross Margin
79%
Oper. Margin
-978%
Profit Margin
-1194%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.75-11.0
52W High
+108.09%
52W Low
+2189%
RSI
58.25
Rel Volume
1.4
Avg Volume
20.84K
Volume
29.2K
Perf Week
8.84%
Perf Month
24.13%
Perf Quarter
419.05%
Perf Half Y
350.59%
-
-
-
-
Beta
1.252
-
-
Volatility
0.83%, 1.1%
Prev Close
-1.51%
Price
22.89
Change
-0.69%
Company Profile
- Volume Average 20.84K
- Market Capitalization 275.43M
- Employee 101
- CEO Mr. Laurent Levy Ph.D.
- Headquarters Paris,FR
- IPO Date 2020-12-11
-
Website
https://www.nanobiotix.com 
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
